|
OXYCONTIN LAWYERS
If you or your family has suffered because of OxyContin, the
manufacturer may have been negligent and failed in its duty to design, make,
inspect and label the product appropriately. Please
contact the oxycontin lawyers of Brown & Crouppen today for your free
initial consultation. Our experienced team of lawyers, medical professionals and
investigators would like to represent you and help equal the odds of your
winning a fair settlement or award from the companies who have put dangerous
drugs into the hands of consumers.
FREE CASE EVALUATION >
|
 |
|
FDA approved in 1995 for treatment of severe to
moderate pain
First marketed in 1996
Active Ingredient: OxyCodone, an opium
derivative also used in Percodan and Percocet
OxyCodone is highly addictive
Increased abuse in urban, suburban, and rural
areas
Emergency room visits related to prescription
drugs containing oxycodone increased from 3,395 in 1993 to 10,825 in
2000
Almost 500 deaths have been attributed to
OxyContin use
Purdue Pharma of Stamford, Conn., manufacturer of the product, has
issued a warning in the form of a "Dear Health Care Professional"
letter, which will be distributed to physicians, pharmacists, and
other health-care professionals to educate them about the risks of the
drug
The Federal Drug Administration (FDA) has
strengthened its precautions in the labeling of OxyContin Tablets,
including issuing their strongest warning – a Black Box Warning.
In 2002, a study of American students found
OxyContin abuse beginning as early as the eighth grade.
The Drug Enforcement Administration (DEA) has
found the highest rates of abuse in West Virginia, Kentucky, Virginia
and Pennsylvania.
At least 1,000 deaths per year are due to
OxyContin abuse.
The DEA is requesting that family physicians and
non-specialists be banned from prescribing the drug.
In August of 2001, Purdue Pharma announced their
blueprint for a “smart pill” that would be harder to abuse than
OxyContin. At that time, the timeframe for the smart pill’s
availability was in the three to five year range.
Perdue Pharma revenue from OxyContin sales -
$1.2 billion in 2003
In January of 2004, the General Accounting
Office (GAO) released a report citing problems with the marketing of
Oxycontin
|
|
|
|
